Literature DB >> 15583321

Azithromycin retards Pseudomonas aeruginosa biofilm formation.

Richard J Gillis1, Barbara H Iglewski.   

Abstract

Using a flow cell biofilm model, we showed that a sub-MIC of azithromycin (AZM) can delay but not inhibit Pseudomonas aeruginosa biofilm formation and results in the development of a stable AZM resistance phenotype. Furthermore, mature biofilms were not affected by AZM.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15583321      PMCID： PMC535287          DOI： 10.1128/JCM.42.12.5842-5845.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  21 in total

1.  Quorum-sensing genes in Pseudomonas aeruginosa biofilms: their role and expression patterns.

Authors:  T R De Kievit; R Gillis; S Marx; C Brown; B H Iglewski
Journal:  Appl Environ Microbiol       Date:  2001-04       Impact factor: 4.792

Review 2.  Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth.

Authors:  N Høiby; H Krogh Johansen; C Moser; Z Song; O Ciofu; A Kharazmi
Journal:  Microbes Infect       Date:  2001-01       Impact factor: 2.700

3.  Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa.

Authors:  K Tateda; R Comte; J C Pechere; T Köhler; K Yamaguchi; C Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Quantification of biofilm structures by the novel computer program COMSTAT.

Authors:  A Heydorn; A T Nielsen; M Hentzer; C Sternberg; M Givskov; B K Ersbøll; S Molin
Journal:  Microbiology       Date:  2000-10       Impact factor: 2.777

5.  Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.

Authors:  A Equi; I M Balfour-Lynn; A Bush; M Rosenthal
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

6.  Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

Authors:  J Wolter; S Seeney; S Bell; S Bowler; P Masel; J McCormack
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

7.  Effect of subminimal inhibitory concentrations of azithromycin on adherence of Pseudomonas aeruginosa to polystyrene.

Authors:  J Vranes
Journal:  J Chemother       Date:  2000-08       Impact factor: 1.714

Review 8.  Cystic fibrosis.

Authors:  Amanda L Brennan; Duncan M Geddes
Journal:  Curr Opin Infect Dis       Date:  2002-04       Impact factor: 4.915

Review 9.  Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease.

Authors:  Thao Nguyen; Stan G Louie; Paul M Beringer; Mark A Gill
Journal:  Curr Opin Pulm Med       Date:  2002-11       Impact factor: 3.155

10.  Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin.

Authors:  Sabine Favre-Bonté; Thilo Köhler; Christian Van Delden
Journal:  J Antimicrob Chemother       Date:  2003-09-01       Impact factor: 5.790
View more
  59 in total

Review 1.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

2.  Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.

Authors:  Sharad Mangal; Rongkun Xu; Heejun Park; Dmitry Zemlyanov; Nivedita Shetty; Yu-Wei Lin; David Morton; Hak-Kim Chan; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-11-07       Impact factor: 4.200

3.  A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing.

Authors:  Mathias Müsken; Stefano Di Fiore; Ute Römling; Susanne Häussler
Journal:  Nat Protoc       Date:  2010-07-29       Impact factor: 13.491

4.  Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach.

Authors:  Yusuf Nalca; Lothar Jänsch; Florian Bredenbruch; Robert Geffers; Jan Buer; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Effect of antibiotic prophylaxis on Coagulase-negative Staphylococcus virulence factor profiles in patients undergoing cataract surgery.

Authors:  Yolanda López; Margarita Samudio; Norma Fariña; Verónica Castillo; Sonia Abente; Martin M Nentwich; Nilsa González-Britez; Florentina Laspina; Agustín Carron; Diógenes Cibils; Herminia Miño de Kaspar
Journal:  Int Ophthalmol       Date:  2016-09-21       Impact factor: 2.031

6.  PA5470 Counteracts Antimicrobial Effect of Azithromycin by Releasing Stalled Ribosome in Pseudomonas aeruginosa.

Authors:  Jing Shi; Yiwei Liu; Yueying Zhang; Yongxin Jin; Fang Bai; Zhihui Cheng; Shouguang Jin; Weihui Wu
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

7.  Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa.

Authors:  Thilo Köhler; Jean-Luc Dumas; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

8.  Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.

Authors:  Xavier Mulet; María D Maciá; Ana Mena; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

9.  Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms.

Authors:  Timothy D Starner; Joshua D Shrout; Matthew R Parsek; Peter C Appelbaum; GunHee Kim
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.